Congress Pushes US FDA On Trial Diversity, Accelerated Approval In Approps Report

 
• By Sarah Karlin-Smith

The House Appropriations Committee indicates in fiscal year 2025 appropriations report language that lawmakers will closely monitor the FDA’s implementation of clinical trial diversity action plans. 

colorful ropes joining together
Congress again raises concerns about a lack of alignment among the FDA's drugs and biologics centers in its appropriations report. • Source: Shutterstock

More from Legislation

More from Pink Sheet